{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:16:55Z","timestamp":1783430215683,"version":"3.54.6"},"reference-count":151,"publisher":"MDPI AG","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAPMA"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:p>This study attempted to determine the cost-effectiveness of therapies for dermatophyte toenail onychomycosis in the United States in 2001. The antimycotic agents evaluated were ciclopirox 8% nail lacquer and the oral agents terbinafine, itraconazole (pulse), itraconazole (continuous), fluconazole, and griseofulvin. A treatment algorithm for the management of onychomycosis was developed, and a meta-analysis was carried out to determine the average mycologic and clinical response rates for the various agents. The cost of the regimen was figured as the sum of the costs of drug acquisition, medical management, and management of adverse effects. The expected cost of management and disease-free days were determined, and a sensitivity analysis was conducted. It was concluded that ciclopirox 8% nail lacquer, which has recently become available in the larger size of 6.6 mL, is a cost-effective agent for the management of toenail onychomycosis. (J Am Podiatr Med Assoc 92(5): 272-286, 2002)<\/jats:p>","DOI":"10.7547\/87507315-92-5-272","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T10:52:42Z","timestamp":1396349562000},"page":"272-286","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of Dermatophyte Toenail Onychomycosis in the United States"],"prefix":"10.3390","volume":"92","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Associate Professor, Division of Dermatology, Department of Medicine, Sunnybrook and Women\u2019s College Health Sciences Center (Sunnybrook campus) and University of Toronto, Toronto, Ontario, Canada. Mailing address: 490 Wonderland Rd S, Ste 6, London, Ontario, Canada N6K 1L6."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"R1","series-title":"J Am Acad Dermatol","first-page":"244","volume":"43","year":"2000","unstructured":"Gupta AK, Jain H, Lynde CW, et al: Prevalence and epidemiology of onychomycosis in patients visiting physicians\u2019 offices: a multicenter Canadian survey of 15,000 patients. .J Am Acad Dermatol43::244. ,2000. .10906646"},{"key":"R2","series-title":"Arch Dermatol","first-page":"1172","volume":"133","year":"1997","unstructured":"Elewski BE, Charif MA: Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. .Arch Dermatol133::1172. ,1997. .9301602"},{"key":"R3","unstructured":"Ciclopirox lacquer topical solution 8% [package insert], Aventis Pharmaceuticals, Inc, Collegeville, PA, December 1999.."},{"key":"R4","series-title":"J Am Acad Dermatol","first-page":"S70","volume":"43 (suppl 4)","year":"2000","unstructured":"Gupta AK, Fleckman P, Baran R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. .J Am Acad Dermatol43 (suppl 4)::S70. ,2000. ."},{"key":"R5","series-title":"J Am Acad Dermatol","first-page":"S81","volume":"43 (suppl 4)","year":"2000","unstructured":"Gupta AK: Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. .J Am Acad Dermatol43 (suppl 4)::S81. ,2000. ."},{"key":"R6","series-title":"Pharmacoeconomics","first-page":"243","volume":"13","year":"1998","unstructured":"Gupta AK: Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails: a US analysis. .Pharmacoeconomics13::243. ,1998. .10178650"},{"key":"R7","series-title":"Br J Dermatol","first-page":"35","volume":"130 (suppl 43)","year":"1994","unstructured":"Arikian SR, Einarson TR, Kobelt-Nguyen G, et al: A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. .Br J Dermatol130 (suppl 43)::35. ,1994. ."},{"key":"R8","series-title":"Dermatology","first-page":"239","volume":"193","year":"1996","unstructured":"Van Doorslaer EKA, Tormans G, Gupta AK, et al: Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. .Dermatology193::239. ,1996. .8944348"},{"key":"R9","series-title":"J Am Acad Dermatol","first-page":"677","volume":"30","year":"1994","unstructured":"Gupta AK, Sauder DN, Shear NH: Antifungal agents: an overview: part I. .J Am Acad Dermatol30::677. ,1994. .8176006"},{"key":"R10","series-title":"J Am Acad Dermatol","first-page":"911","volume":"30","year":"1994","unstructured":"Gupta AK, Sauder DN, Shear NH: Antifungal agents: an overview: part II. .J Am Acad Dermatol30::911. ,1994. .7619094"},{"key":"R11","series-title":"J Am Acad Dermatol","first-page":"217","volume":"42","year":"2000","unstructured":"Tosti A, Piraccini BM, Lorenzi S: Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. .J Am Acad Dermatol42::217. ,2000. .10642676"},{"key":"R12","series-title":"J Eur Acad Dermatol Venereol","first-page":"1","volume":"13","year":"1999","unstructured":"Gupta AK, Shear NH: The new oral agents for onychomycosis of the toenails. .J Eur Acad Dermatol Venereol13::1. ,1999. .10565624"},{"key":"R13","series-title":"Drug Safety","first-page":"33","volume":"22","year":"2000","unstructured":"Gupta AK, Shear NH: An update, with a risk-benefit evaluation of the newer oral antifungal agents to treat onychomycosis. .Drug Safety22::33. ,2000. .10647975"},{"key":"R14","series-title":"J Am Acad Dermatol","first-page":"595","volume":"34","year":"1996","unstructured":"Tosti A, Piraccini BM, Stinchi C, et al: Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. .J Am Acad Dermatol34::595. ,1996. .8601647"},{"key":"R15","series-title":"J Dermatol","first-page":"259","volume":"23","year":"1996","unstructured":"Alpsoy E, Yilmaz E, Basaran E: Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. .J Dermatol23::259. ,1996. .8935341"},{"key":"R16","series-title":"J Am Acad Dermatol","first-page":"485","volume":"44","year":"2001","unstructured":"Gupta AK, Lynde CW, Konnikov N: Single blind randomized study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. .J Am Acad Dermatol44::485. ,2001. .11209119"},{"key":"R17","series-title":"Int J Dermatol","first-page":"586","volume":"30","year":"1991","unstructured":"Arenas R, Fernandez G, Dominguez L: Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. .Int J Dermatol30::586. ,1991. .1657803"},{"key":"R18","series-title":"J Dermatol Treatment","first-page":"93","volume":"8","year":"1997","unstructured":"Baran R, Belaich S, Beylot C, et al: Comparative multicenter double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. .J Dermatol Treatment8::93. ,1997. ."},{"key":"R19","series-title":"J Am Acad Dermatol","first-page":"750","volume":"32","year":"1995","unstructured":"Faergemann J, Anderson C, Hersle K, et al: Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. .J Am Acad Dermatol32::750. ,1995. .7722020"},{"key":"R20","series-title":"Arch Dermatol","first-page":"919","volume":"131","year":"1995","unstructured":"Hofmann J, Bra\u0308utigam M, Weidinger G, et al: Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. .Arch Dermatol131::919. ,1995. .7632064"},{"key":"R21","series-title":"Acta Derm Venereol","first-page":"137","volume":"70","year":"1990","unstructured":"Wals\u00d8e I, Stangerup M, Svejgaard E: Itraconazole in onychomycosis: open and double-blind studies. .Acta Derm Venereol70::137. ,1990. .1969198"},{"key":"R22","series-title":"Int J Dermatol","first-page":"138","volume":"34","year":"1993","unstructured":"Arenas R, Dominguez-Cherit J, Ferna\u0301ndez LM: Open randomized comparison of itraconazole versus terbinafine in onychomycosis. .Int J Dermatol34::138. ,1993. ."},{"key":"R23","series-title":"Br Med J","first-page":"919","volume":"311","year":"1995","unstructured":"Bra\u0308utigam M, Nolting S, Schopf RE, et al: Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. .Br Med J311::919. ,1995. ."},{"key":"R24","series-title":"Br J Dermatol","first-page":"16","volume":"134 (suppl 46)","year":"1996","unstructured":"De Backer M, De Keyser P, De Vroey C, et al: A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg\/day vs. itraconazole 200 mg\/day: a double-blind comparative trial. .Br J Dermatol134 (suppl 46)::16. ,1996. ."},{"key":"R25","series-title":"Acta Derm Venereol","first-page":"221","volume":"79","year":"1999","unstructured":"Degreef HJ, Dejgaard J, Del Palacio A, et al: Randomized double-blind comparison of short term itraconazole and terbinafine therapy for toenail onychomycosis. .Acta Derm Venereol79::221. ,1999. .10384922"},{"key":"R26","series-title":"Cutis","first-page":"217","volume":"59","year":"1997","unstructured":"Elewski BE, Scher RK, Aly R, et al: Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. .Cutis59::217. ,1997. .9104548"},{"key":"R27","series-title":"Eur J Dermatol","first-page":"7","volume":"6","year":"1996","unstructured":"Haneke E, Delescluse J, Plinck E, et al: The use of itraconazole in onychomycosis. .Eur J Dermatol6::7. ,1996. ."},{"key":"R28","series-title":"Br J Dermatol","first-page":"230","volume":"136","year":"1997","unstructured":"Havu V, Brandt H, Heikkila\u0308 H, et al: A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. .Br J Dermatol136::230. ,1997. .9068738"},{"key":"R29","series-title":"J Eur Acad Dermatol","first-page":"215","volume":"9","year":"1997","unstructured":"Honeyman JF, Talarico FS, Arruda LHF, et al: Itraconazole versus terbinafine (LAMISIL): which is better for the treatment of onychomycosis. ?J Eur Acad Dermatol9::215. ,1997. ."},{"key":"R30","series-title":"Int J Dermatol","first-page":"589","volume":"35","year":"1996","unstructured":"Jones HE, Zaias N: Double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. .Int J Dermatol35::589. ,1996. .8854164"},{"key":"R31","series-title":"J Am Acad Dermatol","first-page":"110","volume":"35","year":"1996","unstructured":"Odom R, Daniel R, Aly R: A double blind randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. .J Am Acad Dermatol35::110. ,1996. .8682945"},{"key":"R32","unstructured":"Itraconazole Product Monograph, Janssen Pharmaceutica Inc, Titusville, NJ, 1996.."},{"key":"R33","series-title":"Int J Dermatol","first-page":"70","volume":"36","year":"1997","unstructured":"Bonifaz A, Carrasco-Gerard E, Sau\u0301l A: Itraconazole in onychomycosis: intermittent dose schedule. .Int J Dermatol36::70. ,1997. .9071625"},{"key":"R34","series-title":"J Dermatol Treatment","first-page":"33","volume":"11","year":"2000","unstructured":"Gupta AK, Maddin S, Arlette J, et al: Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. .J Dermatol Treatment11::33. ,2000. ."},{"key":"R35","series-title":"BMJ","first-page":"1031","volume":"318","year":"1999","unstructured":"Evans EG, Sigurgeirsson B, for the LION Study Group: Double-blind randomized study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis. .BMJ318::1031. ,1999. .10205099"},{"key":"R36","series-title":"Mycoses","first-page":"235","volume":"41","year":"1998","unstructured":"Ginter G, De Doncker P: An intermittent 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological patients. .Mycoses41::235. ,1998. .9715639"},{"key":"R37","series-title":"Zeitschrift fuer Hautkrankheiten","first-page":"737","volume":"10","year":"1997","unstructured":"Haneke E, Abeck D, Ring J: The safety and efficacy of intermittent therapy with itraconazole for finger- and toenail onychomycosis: a multicenter trial. .Zeitschrift fuer Hautkrankheiten10::737. ,1997. ."},{"key":"R38","series-title":"Dermatology","first-page":"323","volume":"196","year":"1998","unstructured":"Haneke E, Tajerbashi M, De Doncker P, et al: Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. .Dermatology196::323. ,1998. .9621140"},{"key":"R39","series-title":"Postgrad Med","first-page":"12","volume":"spec no","year":"1999","unstructured":"Kejda J: Itraconazole pulse therapy vs. continuous terbinafine dosing for toenail onychomycosis. .Postgrad Med (spec no)::12. ,1999. .10492661"},{"key":"R40","series-title":"Revista Argentina de Micologica","first-page":"8","volume":"21","year":"1998","unstructured":"Negroni R, Avechvala A, Bonvehi P: Treatment of onychomycosis due to mycelial fungi. .Revista Argentina de Micologica21::8. ,1998. ."},{"key":"R41","unstructured":"Svejgaard E: \u201cPoster P 206.\u201d Presented at the Fifty-sixth Annual Meeting of the American Academy of Dermatology, February 27\u2013March 4, 1998, Orlando, FL.."},{"key":"R42","series-title":"Dermatology","first-page":"47","volume":"199","year":"1999","unstructured":"Wang DL, Wang AP, Li RY, et al: Therapeutic efficacy and safety of 1-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. .Dermatology199::47. ,1999. .10449957"},{"key":"R43","unstructured":"De Backer M, De Keyser P, Massart DL, et al: \u201cTerbinafine (Lamisil) 250 mg\/day and 500 mg\/day Are Equally Effective in a 16 Week Oral Treatment of Toenail Onychomycosis: A Double-Blind Multicentre Trial,\u201d in International Perspective on Lamisil, ed by RJ Hay, p 39, CCT Healthcare Communications, London, 1994.."},{"key":"R44","series-title":"BMJ","first-page":"1151","volume":"304","year":"1992","unstructured":"Goodfield MJD, Andrew L, Evans EGV: Short term treatment of dermatophyte onychomycosis with terbinafine. .BMJ304::1151. ,1992. .1392793"},{"key":"R45","series-title":"Br J Dermatol","first-page":"97","volume":"142","year":"2000","unstructured":"Havu V, Heikkila H, Kuokkanen K, et al: A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. .Br J Dermatol142::97. ,2000. .10651701"},{"key":"R46","series-title":"JAPMA","first-page":"127","volume":"91","year":"2001","unstructured":"Pollack R, Billstein SA: Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations. .JAPMA91::127. ,2001. ."},{"key":"R47","series-title":"Acta Derm Venereol","first-page":"66","volume":"77","year":"1997","unstructured":"Svejgaard EL, Brandrup F, Kragballe K, et al: Oral terbinafine in toenail dermatophytosis. .Acta Derm Venereol77::66. ,1997. .9059684"},{"key":"R48","series-title":"Br J Dermatol","first-page":"737","volume":"136","year":"1997","unstructured":"Tausch I, Bra\u0308utigam M, Weidinger G, et al: Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. .Br J Dermatol136::737. ,1997. .9205509"},{"key":"R49","unstructured":"Terbinafine [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ, 1996.."},{"key":"R50","series-title":"Br J Dermatol","first-page":"36","volume":"126","year":"1992","unstructured":"Van Der Schroeff JG, Cirkel PK, et al: A randomized treatment duration-finding study of terbinafine in onychomycosis. .Br J Dermatol126::36. ,1992. .1531927"},{"key":"R51","series-title":"J Am Acad Dermatol","first-page":"775","volume":"33","year":"1995","unstructured":"Watson A, Marley J, Ellis D, et al: Terbinafine in onychomycosis of the toenail: a novel treatment protocol. .J Am Acad Dermatol33::775. ,1995. .7593777"},{"key":"R52","series-title":"Curr Ther Res","first-page":"481","volume":"58","year":"1997","unstructured":"Fra\u0308ki J, Heikkila\u0308 H, Kero M, et al: An open-label, non-comparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis. .Curr Ther Res58::481. ,1997. ."},{"key":"R53","series-title":"Int J Dermatol","first-page":"587","volume":"35","year":"1996","unstructured":"Montero-Gei F, Robles-Soto ME, Schlager H: Fluconazole in the treatment of severe onychomycosis. .Int J Dermatol35::587. ,1996. .8854163"},{"key":"R54","series-title":"J Am Acad Dermatol","first-page":"S77","volume":"38","year":"1998","unstructured":"Scher RK, Breman D, Rich P, et al: Once-weekly fluconazole (150 mg, 300 mg, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. .J Am Acad Dermatol38::S77. ,1998. .9631989"},{"key":"R55","series-title":"Arch Dermatol","first-page":"859","volume":"81","year":"1960","unstructured":"Goldfarb NJ, Sulzberger MB: Experiences in one hundred thirty-seven patients with oral griseofulvin. .Arch Dermatol81::859. ,1960. .13850642"},{"key":"R56","series-title":"Arch Dermatol","first-page":"838","volume":"60","year":"1960","unstructured":"Kaminsky A: Comparative effects of griseofulvin on onychomycosis and on psoriasis. .Arch Dermatol60::838. ,1960. ."},{"key":"R57","series-title":"Arch Dermatol","first-page":"769","volume":"81","year":"1960","unstructured":"Williams DI: Griseofulvin and Trichophyton rubrum infections. .Arch Dermatol81::769. ,1960. .13844836"},{"key":"R58","series-title":"BMJ","first-page":"464","volume":"3","year":"1967","unstructured":"Davies RR, Everall JD, Hamilton E: Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. .BMJ3::464. ,1967. .20791323"},{"key":"R59","series-title":"Antimicrob Agents Chemother","first-page":"2064","volume":"37","year":"1993","unstructured":"Korting HC, Schafer-Korting M, Zienicke H, et al: Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. .Antimicrob Agents Chemother37::2064. ,1993. .8257124"},{"key":"R60","series-title":"Lancet","first-page":"1140","volume":"1","year":"1960","unstructured":"Russell B, Frain-Bell W, Riddell RW, et al: Chronic ringworm infection of the skin and nails treated with griseofulvin. .Lancet1::1140. ,1960. ."},{"key":"R61","series-title":"Br J Dermatol","first-page":"691","volume":"112","year":"1985","unstructured":"Hay RJ, Clayton YM, Griffiths WA, et al: A comparative double-blind study of ketoconazole and griseofulvin in dermatophytosis. .Br J Dermatol112::691. ,1985. .3890924"},{"key":"R62","series-title":"J Antimicrob Chemother","first-page":"195","volume":"29","year":"1992","unstructured":"Piepponen T, Blomqvist K, Brandt H, et al: Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. .J Antimicrob Chemother29::195. ,1992. .1324238"},{"key":"R63","series-title":"Lancet","first-page":"373","volume":"1","year":"1961","unstructured":"Stevenson CJ, Djavahizwili N: Chronic ringworm of the nails. .Lancet1::373. ,1961. ."},{"key":"R64","series-title":"Arch Dermatol","first-page":"827","volume":"81","year":"1960","unstructured":"Levin H, Alden HS, Ajello L: Use of griseofulvin in office practice. .Arch Dermatol81::827. ,1960. .14416209"},{"key":"R65","series-title":"JAPA","first-page":"119","volume":"56","year":"1966","unstructured":"Quintaville P: Onychomycosis treated with ultrafine griseofulvin. .JAPA56::119. ,1966. ."},{"key":"R66","series-title":"Arch Dermatol","first-page":"192","volume":"81","year":"1960","unstructured":"Dillaha CJ, Jansen GT: Dosage requirements of griseofulvin in onychomycosis due to Trichophyton rubrum. .Arch Dermatol81::192. ,1960. ."},{"key":"R67","series-title":"JAMA","first-page":"2168","volume":"171","year":"1959","unstructured":"Blank H, Smith GJ, Roth FJ, et al: Griseofulvin for the systemic treatment of dermatomycoses. .JAMA171::2168. ,1959. ."},{"key":"R68","series-title":"Arch Dermatol","first-page":"733","volume":"18","year":"1960","unstructured":"Maibach HI, Klingman AM: Short-term treatment of onychomycosis with griseofulvin. .Arch Dermatol18::733. ,1960. ."},{"key":"R69","series-title":"Arch Dermatol","first-page":"833","volume":"81","year":"1960","unstructured":"Gonza\u0301lez-Ochoa A, Ahumada-Padilla M: New schemes in the treatment of dermatophytoses with griseofulvin. .Arch Dermatol81::833. ,1960. .13851014"},{"key":"R70","series-title":"J Am Acad Dermatol","first-page":"72","volume":"32","year":"1995","unstructured":"Haneke E, Tausch I, Bra\u0308utigam M, et al: Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. .J Am Acad Dermatol32::72. ,1995. .7822520"},{"key":"R71","series-title":"Br J Dermatol","first-page":"358","volume":"72","year":"1960","unstructured":"Hargreaves GK: The treatment of onychomycosis with griseofulvin. .Br J Dermatol72::358. ,1960. .13711555"},{"key":"R72","series-title":"J Am Acad Dermatol","first-page":"1052","volume":"32","year":"1995","unstructured":"Andre\u0301 J, De Doncker P, Laporet M, et al: Onychomycosis caused by Microsporum canis: treatment with itraconazole. .J Am Acad Dermatol32::1052. ,1995. .7751453"},{"key":"R73","series-title":"J Am Acad Dermatol","first-page":"1077","volume":"18","year":"1988","unstructured":"Hanifin JM, Tofte SJ: Itraconazole therapy for recalcitrant dermatophyte infections. .J Am Acad Dermatol18::1077. ,1988. .2838534"},{"key":"R74","series-title":"J Dermatol Treatment","first-page":"145","volume":"2","year":"1992","unstructured":"Rongioletti F, Robert E, Tripodi S, et al: Treatment of onychomycosis with itraconazole. .J Dermatol Treatment2::145. ,1992. ."},{"key":"R75","unstructured":"Stary A, Storch M, Ho\u0308rting-Mu\u0308ller I: Systemic treatment of onychomycosis with itraconazole: clinical and mycological results [abstract]. Presented at the Third Congress of the European Academy of Dermatology and Venereology, September 26\u201330, 1993, Copenhagen.."},{"key":"R76","series-title":"Br J Dermatol","first-page":"359","volume":"119","year":"1988","unstructured":"Hay RJ, Clayton YM, Moore MK, et al: An evaluation of itraconazole in the management of onychomycosis. .Br J Dermatol119::359. ,1988. .2846030"},{"key":"R77","series-title":"Arch Dermatol","first-page":"19","volume":"130","year":"1994","unstructured":"DePadova-Elder SM, Ditre CM, Kantor GR, et al: Candidiasis endocrinopathy syndrome. .Arch Dermatol130::19. ,1994. .8285736"},{"key":"R78","series-title":"Curr Ther Res","first-page":"1066","volume":"56","year":"1995","unstructured":"Kim JA, Ahn KJ, Kim JM, et al: Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. .Curr Ther Res56::1066. ,1995. ."},{"key":"R79","series-title":"J Am Acad Dermatol","first-page":"173","volume":"36","year":"1997","unstructured":"De Doncker PRG, Scher RK, Baran RL, et al: Itraconazole therapy is effective for pedal onychomycosis caused by some non-dermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 35 patients. .J Am Acad Dermatol36::173. ,1997. .9039163"},{"key":"R80","series-title":"Br J Dermatol","first-page":"47","volume":"118","year":"1988","unstructured":"Hay RJ, Baran R, Moore MK, et al: Candida onychomycosis: an evaluation of the role of Candida species in nail disease. .Br J Dermatol118::47. ,1988. .3342176"},{"key":"R81","series-title":"Cutis","first-page":"371","volume":"58","year":"1996","unstructured":"Kirshbaum BA: Itraconazole therapy for onychomycosis: case reports. .Cutis58::371. ,1996. .8934081"},{"key":"R82","series-title":"Pediatr Dermatol","first-page":"146","volume":"14","year":"1997","unstructured":"Tosti A, Piraccini BM, Vincenzi C, et al: Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis. .Pediatr Dermatol14::146. ,1997. .9144703"},{"key":"R83","series-title":"J Am Acad Dermatol","first-page":"731","volume":"26","year":"1992","unstructured":"Willemsen M, De Doncker P, Willems J, et al: Posttreatment itraconazole levels in the nail. .J Am Acad Dermatol26::731. ,1992. .1316389"},{"key":"R84","series-title":"Br J Dermatol","first-page":"96","volume":"140","year":"1999","unstructured":"Havu V, Brandt H, Heikkila H, et al: Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. .Br J Dermatol140::96. ,1999. .10215775"},{"key":"R85","series-title":"Arch Dermatol","first-page":"34","volume":"132","year":"1996","unstructured":"De Doncker P, Decroix J, Pierard GE, et al: Itraconazole pulse therapy is effective in the treatment of onychomycosis: a pharmacokinetic\/pharmacodynamic and clinical evaluation. .Arch Dermatol132::34. ,1996. .8546481"},{"key":"R86","series-title":"Dermatol Clin","first-page":"121","volume":"15","year":"1997","unstructured":"Gupta AK, Scher RK, De Doncker P: Current management of onychomycosis: an overview. .Dermatol Clin15::121. ,1997. .9001866"},{"key":"R87","series-title":"Cutis","first-page":"180","volume":"56","year":"1995","unstructured":"De Doncker P, Van Lint J, Dockx P, et al: Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. .Cutis56::180. ,1995. .8565605"},{"key":"R88","series-title":"Mycoses","first-page":"397","volume":"40","year":"1997","unstructured":"Wu J, Wen H, Liao W: Small-dose itraconazole pulse therapy in the treatment of onychomycosis. .Mycoses40::397. ,1997. .9470430"},{"key":"R89","series-title":"J Eur Acad Dermatol Venereol","first-page":"109","volume":"11","year":"1998","unstructured":"Ramos-e-Silva M, Marques SA, Gontijo B, et al: Efficacy and safety of itraconazole pulse therapy: Brazilian multicentric study on toenail onychomycosis caused by dermatophytes. .J Eur Acad Dermatol Venereol11::109. ,1998. .9784035"},{"key":"R90","series-title":"Dermatology","first-page":"406","volume":"192","year":"1996","unstructured":"Luyton C, Andre\u0301 J, Walraevens C, et al: Yellow nail syndrome and onychomycosis. .Dermatology192::406. ,1996. .8864394"},{"key":"R91","series-title":"Cutis","first-page":"253","volume":"60","year":"1997","unstructured":"Elewski BE: Trichophyton rubrum onychomycosis in a 17-year-old girl. .Cutis60::253. ,1997. .9403245"},{"key":"R92","series-title":"J Am Acad Dermatol","first-page":"231","volume":"36","year":"1997","unstructured":"Odom RB, Aly R, Scher RK, et al: A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. .J Am Acad Dermatol36::231. ,1997. .9039174"},{"key":"R93","series-title":"Mycoses","first-page":"93","volume":"42","year":"1999","unstructured":"Chen J, Liao W, Wen H, et al: A comparison among four regimens of itraconazole treatment in onychomycosis. .Mycoses42::93. ,1999. .10394855"},{"key":"R94","series-title":"JAPMA","first-page":"339","volume":"89","year":"1999","unstructured":"Albreski DA, Gross EG: The safety of itraconazole in the diabetic population. .JAPMA89::339. ,1999. ."},{"key":"R95","series-title":"J Am Acad Dermatol","first-page":"479","volume":"44","year":"2001","unstructured":"Gupta AK, Konnikov N, Lynde CW: Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. .J Am Acad Dermatol44::479. ,2001. .11209118"},{"key":"R96","series-title":"Arch Pediatr Adolesc Med","first-page":"614","volume":"154","year":"2000","unstructured":"Huang PH, Paller AS: Itraconazole pulse therapy for dermatophyte onychomycosis in children. .Arch Pediatr Adolesc Med154::614. ,2000. .10850511"},{"key":"R97","series-title":"Dermatology","first-page":"248","volume":"199","year":"1999","unstructured":"Gupta AK, Nolting S, de Prost Y, et al: The use of itraconazole to treat cutaneous fungal infections in children. .Dermatology199::248. ,1999. .10592406"},{"key":"R98","series-title":"Pediatr Dermatol","first-page":"472","volume":"15","year":"1998","unstructured":"Gupta AK, Adam P, Hofstader SL: Itraconazole oral solution for the treatment of onychomycosis. .Pediatr Dermatol15::472. ,1998. .9875972"},{"key":"R99","series-title":"J Am Acad Dermatol","first-page":"395","volume":"36","year":"1997","unstructured":"Gupta AK, Sibbald RG, Lynde CW, et al: Onychomycosis in children: prevalence and treatment strategies. .J Am Acad Dermatol36::395. ,1997. .9091470"},{"key":"R100","series-title":"Arch Dermatol","first-page":"940","volume":"136","year":"2000","unstructured":"Zaias N, Rebell G: Onychomycosis treated until the nail is replaced by normal growth or there is failure. .Arch Dermatol136::940. ,2000. ."},{"key":"R101","series-title":"Int J Dermatol","first-page":"374","volume":"35","year":"1996","unstructured":"Galimberti R, Kowalczuk A, Flores V, et al: Onychomycosis treated with a short course of oral terbinafine. .Int J Dermatol35::374. ,1996. .8734666"},{"key":"R102","series-title":"Mycoses","first-page":"211","volume":"38","year":"1995","unstructured":"Albanese G, Di Cintio R, Martini C, et al: Short therapy for tinea unguium with terbinafine: four different courses of treatment. .Mycoses38::211. ,1995. .8531933"},{"key":"R103","series-title":"Dermatologica","first-page":"174","volume":"181","year":"1990","unstructured":"Rakosi T: Terbinafine and onychomycosis [abstract]. .Dermatologica181::174. ,1990. ."},{"key":"R104","series-title":"Lancet","first-page":"1066","volume":"339","year":"1992","unstructured":"Shuster S, Munro C: Single dose treatment of fungal nail disease [letter]. .Lancet339::1066. ,1992. .1349100"},{"key":"R105","series-title":"J Am Acad Dermatol","first-page":"810","volume":"23","year":"1990","unstructured":"Zaias N: Management of onychomycosis with oral terbinafine. .J Am Acad Dermatol23::810. ,1990. .2146293"},{"key":"R106","series-title":"Br J Dermatol","first-page":"40","volume":"126","year":"1992","unstructured":"Baudraz-Rosselet F, Rakosi T, Wili PB, et al: Treatment of onychomycosis with terbinafine. .Br J Dermatol126::40. ,1992. .1531928"},{"key":"R107","series-title":"Br J Dermatol","first-page":"753","volume":"121","year":"1989","unstructured":"Goodfield MJD, Rowell NR, Forster RA, et al: Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. .Br J Dermatol121::753. ,1989. .2532927"},{"key":"R108","series-title":"Br J Dermatol","first-page":"33","volume":"126","year":"1992","unstructured":"Goodfield MJD: Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. .Br J Dermatol126::33. ,1992. .1531926"},{"key":"R109","series-title":"J Dermatol Treatment","first-page":"55","volume":"1","year":"1990","unstructured":"Goodfield MJD: Clinical results with terbinafine in onychomycosis. .J Dermatol Treatment1::55. ,1990. ."},{"key":"R110","series-title":"Clin Exp Dermatol","first-page":"120","volume":"14","year":"1989","unstructured":"Zaias N, Serrano L: The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. .Clin Exp Dermatol14::120. ,1989. .2532084"},{"key":"R111","series-title":"Int J Dermatol","first-page":"918","volume":"32","year":"1993","unstructured":"Savin RC, Atton AV: Terbinafine in onychomycosis: a mini study. .Int J Dermatol32::918. ,1993. .8125705"},{"key":"R112","series-title":"N Z Med J","first-page":"17","volume":"104","year":"1991","unstructured":"Eastcott DF: Terbinafine and onychomycosis [letter]. .N Z Med J104::17. ,1991. ."},{"key":"R113","series-title":"Br J Dermatol","first-page":"329","volume":"133","year":"1995","unstructured":"Wong CK, Cho YL: Very short duration therapy with oral terbinafine for fingernail onychomycosis. .Br J Dermatol133::329. ,1995. .7547412"},{"key":"R114","series-title":"Br J Dermatol","first-page":"16","volume":"130","year":"1994","unstructured":"Nolting S, Bra\u0308utigam M, Weidinger G: Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. .Br J Dermatol130::16. ,1994. .8186136"},{"key":"R115","series-title":"J Am Acad Dermatol","first-page":"958","volume":"35","year":"1996","unstructured":"Segal R, Kritzman A, Cividalli L, et al: Treatment of Candida nail infections with terbinafine. .J Am Acad Dermatol35::958. ,1996. .8959955"},{"key":"R116","series-title":"J Dermatol Treatment","first-page":"39","volume":"3","year":"1992","unstructured":"Roberts DT, Richardson MD, Dwyer PK, et al: Terbinafine in chronic paronychia and Candida onychomycosis. .J Dermatol Treatment3::39. ,1992. ."},{"key":"R117","series-title":"Br J Dermatol","first-page":"799","volume":"135","year":"1996","unstructured":"Tosti A, Piraccini BM, Stinchi C, et al: Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. .Br J Dermatol135::799. ,1996. .8977686"},{"key":"R118","series-title":"Transplant Proc","first-page":"1488","volume":"28","year":"1996","unstructured":"Lee KH, Kim YS, Kim MS, et al: Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. .Transplant Proc28::1488. ,1996. .8658754"},{"key":"R119","series-title":"Br J Dermatol","first-page":"144","volume":"133","year":"1995","unstructured":"Velthuis PJ, Nijenhuis M: Treatment of onychomycosis with terbinafine in patients with Down\u2019s syndrome. .Br J Dermatol133::144. ,1995. ."},{"key":"R120","series-title":"Mycoses","first-page":"63","volume":"41","year":"1998","unstructured":"To\u0308ro\u0308k I, Simon G, Dobozy A, et al: Long-term post-treatment follow-up of onychomycosis treated with terbinafine: a multicentre trial. .Mycoses41::63. ,1998. .9610137"},{"key":"R121","series-title":"Br J Dermatol","first-page":"22","volume":"134","year":"1996","unstructured":"Nandwani R, Parnell A, Youle M, et al: Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. .Br J Dermatol134::22. ,1996. ."},{"key":"R122","series-title":"Br J Dermatol","first-page":"577","volume":"137","year":"1997","unstructured":"Herranz P, Garci\u0301a J, De Lucas R, et al: Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. .Br J Dermatol137::577. ,1997. .9390334"},{"key":"R123","series-title":"Int J Dermatol","first-page":"377","volume":"38","year":"1999","unstructured":"Billstein S, Kianifard F, Justice A: Terbinafine vs. placebo for onychomycosis in black patients. .Int J Dermatol38::377. ,1999. .10369551"},{"key":"R124","series-title":"Int J Dermatol","first-page":"861","volume":"39","year":"2000","unstructured":"Smith EB, Stein LF, Fivenson DP, et al: The safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. .Int J Dermatol39::861. ,2000. .11123452"},{"key":"R125","series-title":"J Am Acad Dermatol","first-page":"654","volume":"39","year":"1998","unstructured":"Ungpakorn R, Reangchainam S, Kullavanijaya P: Onychomycosis in a 2-year-old child successfully treated with oral terbinafine. .J Am Acad Dermatol39::654. ,1998. .9777781"},{"key":"R126","series-title":"Int J Dermatol","first-page":"815","volume":"37","year":"1998","unstructured":"Gupta AK, Scher RK, Rich P: Fluconazole for the treatment of onychomycosis: an update. .Int J Dermatol37::815. ,1998. .9865864"},{"key":"R127","series-title":"J Dermatol Treatment","first-page":"115","volume":"3","year":"1992","unstructured":"Kuokkanen K, Alava S: Fluconazole in the treatment of onychomycosis caused by dermatophytes. .J Dermatol Treatment3::115. ,1992. ."},{"key":"R128","series-title":"J Am Acad Dermatol","first-page":"S87","volume":"38","year":"1998","unstructured":"Drake L, Babel D, Stewart DM, et al: Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. .J Am Acad Dermatol38::S87. ,1998. .9631990"},{"key":"R129","series-title":"J Am Acad Dermatol","first-page":"S95","volume":"38","year":"1998","unstructured":"Ling MR, Swinyer LJ, Jarratt MT, et al: Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. .J Am Acad Dermatol38::S95. ,1998. .9631991"},{"key":"R130","series-title":"J Am Acad Dermatol","first-page":"S103","volume":"38","year":"1998","unstructured":"Rich P, Scher RK, Breneman D, et al: Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. .J Am Acad Dermatol38::S103. ,1998. .9631992"},{"key":"R131","series-title":"J Am Acad Dermatol","first-page":"S110","volume":"38","year":"1998","unstructured":"Savin RC, Drake L, Babel D, et al: Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. .J Am Acad Dermatol38::S110. ,1998. .9631993"},{"key":"R132","series-title":"J Am Acad Dermatol","first-page":"216","volume":"35","year":"1996","unstructured":"Assaf RR, Elewski BE: Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. .J Am Acad Dermatol35::216. ,1996. .8708024"},{"key":"R133","series-title":"Pediatr Dermatol","first-page":"493","volume":"13","year":"1996","unstructured":"Aihara Y, Mori M, Yokota S: Successful treatment of onychomycosis with fluconazole in two patients with hyperimmunoglobulin E syndrome. .Pediatr Dermatol13::493. ,1996. .8987061"},{"key":"R134","series-title":"South Med J","first-page":"1217","volume":"88","year":"1995","unstructured":"Smith SW, Sealy DP, Schneider E, et al: An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. .South Med J88::1217. ,1995. .7502113"},{"key":"R135","series-title":"Arch Dermatol","first-page":"909","volume":"28","year":"1992","unstructured":"Coldiron B: Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. .Arch Dermatol28::909. ,1992. ."},{"key":"R136","series-title":"Dermatology","first-page":"59","volume":"186","year":"1993","unstructured":"Nahass GT, Sisto M: Onychomycosis: successful treatment with once-weekly fluconazole. .Dermatology186::59. ,1993. .8435519"},{"key":"R137","series-title":"J Geriatr Dermatol","first-page":"169","volume":"1","year":"1993","unstructured":"Hochman LG, Scher RK, Meyerson MS, et al: The safety and efficacy of oral fluconazole in the treatment of onychomycosis. .J Geriatr Dermatol1::169. ,1993. ."},{"key":"R138","series-title":"Control Clin Trials","first-page":"177","volume":"7","year":"1986","unstructured":"DerSimonian R, Laird NM: Meta-analysis in clinical trials. .Control Clin Trials7::177. ,1986. .3802833"},{"key":"R139","series-title":"Med Hypotheses","first-page":"192","volume":"35","year":"1991","unstructured":"Velanovich V: Meta-analysis for combining Bayesian probabilities. .Med Hypotheses35::192. ,1991. .1943862"},{"key":"R140","series-title":"Br J Dermatol","first-page":"61","volume":"126 (suppl 39)","year":"1992","unstructured":"Villars VV, Jones TC: Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. .Br J Dermatol126 (suppl 39)::61. ,1992. ."},{"key":"R141","series-title":"J Am Acad Dermatol","first-page":"969","volume":"37","year":"1997","unstructured":"De Doncker P, Gupta AK, Marynissen G, et al: Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. .J Am Acad Dermatol37::969. ,1997. .9418766"},{"key":"R142","series-title":"J Am Acad Dermatol","first-page":"S77","volume":"38","year":"1998","unstructured":"Elewski BE: Once-weekly fluconazole in the treatment of onychomycosis. .J Am Acad Dermatol38::S77. ,1998. .9631989"},{"key":"R143","unstructured":"Drug Topics Red Book: Pharmacy\u2019s Fundamental Reference, p 1, Medical Economics Co, Montvale, NJ, 2000.."},{"key":"R144","unstructured":"Health Care Financing Administration: 1995 Annual Medicare Physician Fee Schedule: Carrier File, Empire New York Carrier, Baltimore, 1995.."},{"key":"R145","unstructured":"Health Care Financing Administration: 1995 Clinical Diagnostic Lab Fee Schedule: Carrier File, Empire New York Carrier, Baltimore, 1995.."},{"key":"R146","series-title":"Int J Dermatol","first-page":"53","volume":"38 (suppl 2)","year":"1999","unstructured":"Gupta AK, Lambert J: Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. .Int J Dermatol38 (suppl 2)::53. ,1999. ."},{"key":"R147","series-title":"Dermatol Clin","first-page":"535","volume":"15","year":"1997","unstructured":"Katz HI, Gupta AK: Oral antifungal drug interactions. .Dermatol Clin15::535. ,1997. .9189688"},{"key":"R148","series-title":"J Am Acad Dermatol","first-page":"237","volume":"41","year":"1999","unstructured":"Gupta AK, Katz HI, Shear NH: Drug interactions with itraconazole, fluconazole and terbinafine, and their management. .J Am Acad Dermatol41::237. ,1999. .10426895"},{"key":"R149","series-title":"Drugs Aging","first-page":"397","volume":"16","year":"2000","unstructured":"Gupta AK: Onychomycosis in the elderly. .Drugs Aging16::397. ,2000. .10939306"},{"key":"R150","series-title":"J Am Acad Dermatol","first-page":"S96","volume":"43","year":"2000","unstructured":"Gupta AK, Baran R: Ciclopirox nail lacquer solution 8% in the 21st century. .J Am Acad Dermatol43::S96. ,2000. .11051138"},{"key":"R151","series-title":"Lancet","first-page":"1766","volume":"357","year":"2001","unstructured":"Ahmad SR, Singer SJ, Leissa BG: Congestive heart failure associated with itraconazole. .Lancet357::1766. ,2001. .11403818"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/japmaonline.org\/view\/journals\/apms\/92\/5\/87507315-92-5-272.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/92\/5\/272\/1414436\/87507315-92-5-272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/92\/5\/87507315-92-5-272.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/92\/5\/87507315-92-5-272.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:45:17Z","timestamp":1783428317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/92\/5\/272"}},"subtitle":["A Pharmacoeconomic Analysis"],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":151,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.7547\/87507315-92-5-272","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}